Loading…
CUE
Cue Biopharma, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 22978P205
$27.88-0.99%Price as of Aug 29, 18:31 UTC · updated once a day, after the close
Key metrics
- Market cap
- $202.53M
- P/E
- —
- Forward P/E
- —
- P/B
- 63.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$29.46
- ROE
- -1603.48%
- Profit margin
- 0.00%
- Revenue growth
- +166.70%
- Beta
- 2.47
- 52-week high
- $45.50
- 52-week low
- $4.98
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -91.4% over 5Y.
today you would have $71.86▼ -92.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $9.15 | $32.70 | $79.20 | $85.50 | |
| P/S | 15.0x | 1.1x | 7.3x | 22.7x | 98.5x |
| P/B | 2.6x | 1.1x | 3.9x | 3.4x | 1.9x |
| EPS | -$8.40 | -$21.60 | -$33.30 | -$44.70 | |
| Profit margin | -681.03% | -96.85% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RXSTRxSight, Inc. | $4.85 | — | 0.8x | — | -17.34% | $201.73M |
| PLXProtalix BioTherapeutics, Inc. | $2.54 | 11.5x | 3.0x | — | 31.23% | $204.65M |
| PDEXPro Dex Inc | $62.56 | 17.9x | 4.4x | — | 29.83% | $199.72M |
| ARMPArmata Pharmaceuticals, Inc. | $5.37 |
About the company
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
- 29
- Boston, United States
Company description provided by Yahoo Finance.